Squarepoint
JANX icon

Squarepoint’s Janux Therapeutics JANX Stock Holding History

Squarepoint’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18M Sell
532,321
-71,679
-12% -$1.04M 0.01% 1238
2026
Q1 		$8.4M Buy
604,000
+213,048
+54% +$2.92M 0.01% 1166
2025
Q4 		$5.4M Buy
390,952
+324,791
+491% +$7.64M 0.01% 1406
2025
Q3 		$1.62M Sell
66,161
-123,408
-65% -$3.01M ﹤0.01% 2278
2025
Q2 		$4.38M Buy
189,569
+132,121
+230% +$3.48M ﹤0.01% 1547
2025
Q1 		$1.55M Buy
57,448
+16,272
+40% +$613K ﹤0.01% 2299
2024
Q4 		$2.2M Buy
41,176
+25,034
+155% +$1.32M ﹤0.01% 2327
2024
Q3 		$733K Sell
16,142
-16,720
-51% -$727K ﹤0.01% 2837
2024
Q2 		$1.38M Sell
32,862
-10,289
-24% -$483K ﹤0.01% 2328
2024
Q1 		$1.62M Sell
43,151
-18,017
-29% -$392K ﹤0.01% 2236
2023
Q4 		$656K Buy
61,168
+50,521
+475% +$437K ﹤0.01% 2811
2023
Q3 		$107K Sell
10,647
-17,133
-62% -$198K ﹤0.01% 3550
2023
Q2 		$330K Buy
27,780
+14,613
+111% +$195K ﹤0.01% 2908
2023
Q1 		$159K Buy
+13,167
New +$219K ﹤0.01% 2869

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Squarepoint's JANX Position: Q2 2026 in Review

Squarepoint reduced its Janux Therapeutics (JANX) stake by 12% in Q2 2026, selling an estimated $1.04M and leaving 532,321 shares worth $8.18M. The position accounts for 0.01% of the portfolio, ranked #1238.

Squarepoint first reported a position in JANX in Q1 2023 and has held it in 14 quarters since. The position peaked at $8.4M in Q1 2026. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Squarepoint held 532,321 shares of Janux Therapeutics worth $8.18M as of Q2 2026.
  • Squarepoint sold 71,679 Janux Therapeutics shares in Q2 2026, an estimated $1.04M.
  • Janux Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1238 holding.
  • Squarepoint first reported a position in Janux Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Squarepoint's Janux Therapeutics position peaked at $8.4M in Q1 2026.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.